These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 28320519)
1. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab. Nerrant E; Thouvenot E; Castelnovo G Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519 [No Abstract] [Full Text] [Related]
2. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246 [TBL] [Abstract][Full Text] [Related]
3. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597 [TBL] [Abstract][Full Text] [Related]
4. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease. Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069 [No Abstract] [Full Text] [Related]
5. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038 [TBL] [Abstract][Full Text] [Related]
6. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab]. Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573 [TBL] [Abstract][Full Text] [Related]
7. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis. Gao J; Jones J; Damato EM; Coles A J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387 [No Abstract] [Full Text] [Related]
8. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915 [No Abstract] [Full Text] [Related]
9. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness. Whiteside D; Barth S; Datta A; Trip SA Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788 [TBL] [Abstract][Full Text] [Related]
10. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion. Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587 [TBL] [Abstract][Full Text] [Related]
11. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis. Ahrabian D; Neill L; Bell R; Leary SM Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216 [TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914 [No Abstract] [Full Text] [Related]